These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 27498862)

  • 41. Personalized treatment based on mini patient-derived xenografts and WES/RNA sequencing in a patient with metastatic duodenal adenocarcinoma.
    Zhao P; Chen H; Wen D; Mou S; Zhang F; Zheng S
    Cancer Commun (Lond); 2018 Aug; 38(1):54. PubMed ID: 30139386
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Metabolomic profiling of pancreatic adenocarcinoma reveals key features driving clinical outcome and drug resistance.
    Kaoutari AE; Fraunhoffer NA; Hoare O; Teyssedou C; Soubeyran P; Gayet O; Roques J; Lomberk G; Urrutia R; Dusetti N; Iovanna J
    EBioMedicine; 2021 Apr; 66():103332. PubMed ID: 33862584
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Irreversible JNK1-JUN inhibition by JNK-IN-8 sensitizes pancreatic cancer to 5-FU/FOLFOX chemotherapy.
    Lipner MB; Peng XL; Jin C; Xu Y; Gao Y; East MP; Rashid NU; Moffitt RA; Herrera Loeza SG; Morrison AB; Golitz BT; Vaziri C; Graves LM; Johnson GL; Yeh JJ
    JCI Insight; 2020 Apr; 5(8):. PubMed ID: 32213714
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacogenomic modeling of circulating tumor and invasive cells for prediction of chemotherapy response and resistance in pancreatic cancer.
    Yu KH; Ricigliano M; Hidalgo M; Abou-Alfa GK; Lowery MA; Saltz LB; Crotty JF; Gary K; Cooper B; Lapidus R; Sadowska M; O'Reilly EM
    Clin Cancer Res; 2014 Oct; 20(20):5281-9. PubMed ID: 25107917
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Precision Medicine and Pancreatic Cancer.
    George B
    Surg Oncol Clin N Am; 2021 Oct; 30(4):693-708. PubMed ID: 34511190
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mathematical Modeling to Address Challenges in Pancreatic Cancer.
    Dogra P; Ramírez JR; Peláez MJ; Wang Z; Cristini V; Parasher G; Rawat M
    Curr Top Med Chem; 2020; 20(5):367-376. PubMed ID: 31893993
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Integration of Pan-Cancer Cell Line and Single-Cell Transcriptomic Profiles Enables Inference of Therapeutic Vulnerabilities in Heterogeneous Tumors.
    Zhang W; Maeser D; Lee A; Huang Y; Gruener RF; Abdelbar IG; Jena S; Patel AG; Huang RS
    Cancer Res; 2024 Jun; 84(12):2021-2033. PubMed ID: 38581448
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Ex vivo modeling of acquired drug resistance in BRAF - mutated pancreatic cancer organoids uncovers individual therapeutic vulnerabilities.
    Steiner S; Pliego-Mendieta A; Haberecker M; Hussung S; Kollár A; Fritsch R; Arnold F; Lenggenhager D; Planas-Paz L; Pauli C
    Cancer Lett; 2024 Mar; 584():216650. PubMed ID: 38246222
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Precision medicine in pancreatic cancer: treating every patient as an exception.
    Herbst B; Zheng L
    Lancet Gastroenterol Hepatol; 2019 Oct; 4(10):805-810. PubMed ID: 31511204
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Identification of treatment-induced vulnerabilities in pancreatic cancer patients using functional model systems.
    Peschke K; Jakubowsky H; Schäfer A; Maurer C; Lange S; Orben F; Bernad R; Harder FN; Eiber M; Öllinger R; Steiger K; Schlitter M; Weichert W; Mayr U; Phillip V; Schlag C; Schmid RM; Braren RF; Kong B; Demir IE; Friess H; Rad R; Saur D; Schneider G; Reichert M
    EMBO Mol Med; 2022 Apr; 14(4):e14876. PubMed ID: 35119792
    [TBL] [Abstract][Full Text] [Related]  

  • 51. 3D imaging analysis on an organoid-based platform guides personalized treatment in pancreatic ductal adenocarcinoma.
    Kang Y; Deng J; Ling J; Li X; Chiang YJ; Koay EJ; Wang H; Burks JK; Chiao PJ; Hurd MW; Bhutani MS; Lee JH; Weston BR; Maitra A; Ikoma N; Tzeng CD; Lee JE; DePinho RA; Wolff RA; Pant S; McAllister F; Katz MH; Fleming JB; Kim MP
    J Clin Invest; 2022 Dec; 132(24):. PubMed ID: 36282600
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Patient-Derived Organoid Pharmacotyping Guides Precision Medicine for Pancreatic Cancer.
    Zhang Y; Houchen CW; Li M
    Clin Cancer Res; 2022 Aug; 28(15):3176-3178. PubMed ID: 35617521
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Using a rhabdomyosarcoma patient-derived xenograft to examine precision medicine approaches and model acquired resistance.
    Monsma DJ; Cherba DM; Richardson PJ; Vance S; Rangarajan S; Dylewski D; Eugster E; Scott SB; Beuschel NL; Davidson PJ; Axtell R; Mitchell D; Lester EP; Junewick JJ; Webb CP; Monks NR
    Pediatr Blood Cancer; 2014 Sep; 61(9):1570-7. PubMed ID: 24687871
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pancreatic ductal adenocarcinoma ubiquitination profiling reveals specific prognostic and theranostic markers.
    El Kaoutari A; Fraunhoffer NA; Audebert S; Camoin L; Berthois Y; Gayet O; Roques J; Bigonnet M; Bongrain C; Ciccolini J; Iovanna JL; Dusetti NJ; Soubeyran P
    EBioMedicine; 2023 Jun; 92():104634. PubMed ID: 37257316
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Precision Oncology in Pancreatic Cancer. From Surgery- to Genetic-Based Chemotherapy.
    Domínguez-Rosado I; Meléndez-Zajgla J
    Rev Invest Clin; 2020 Dec; 72(6):333-336. PubMed ID: 33057318
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Combating pancreatic cancer chemoresistance by triggering multiple cell death pathways.
    Santofimia-Castaño P; Iovanna J
    Pancreatology; 2021 Apr; 21(3):522-529. PubMed ID: 33516629
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Patient-derived organoids, creating a new window of opportunities for pancreatic cancer patients.
    Sandhya S; Hogenson TL; Fernandez-Zapico ME
    EMBO Mol Med; 2022 Apr; 14(4):e15707. PubMed ID: 35285156
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pancreatic cancer genomes: toward molecular subtyping and novel approaches to diagnosis and therapy.
    Wood LD
    Mol Diagn Ther; 2013 Oct; 17(5):287-97. PubMed ID: 23757204
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The war against pancreatic cancer in 2020 - advances on all fronts.
    Jain T; Dudeja V
    Nat Rev Gastroenterol Hepatol; 2021 Feb; 18(2):99-100. PubMed ID: 33414515
    [No Abstract]   [Full Text] [Related]  

  • 60. The case for a stratified application of targeted agents against pancreatic cancer.
    Bijlsma MF
    EBioMedicine; 2021 May; 67():103344. PubMed ID: 33910122
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.